OncoZenge AB (publ) (8LY.F)

0.3155 +0.0035 (+1.12%) At close: 08:20AM CEST

OncoZenge AB (publ)

Gustavslundsvägen 34
Bromma 167 51
Sweden
46 8 31 14 20
https://oncozenge.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stian Kildal	Chief Executive Officer	N/A	N/A	N/A
Mr. Michael Owens B.A., B.S., B.S.B.A	Chief Financial Officer	N/A	N/A	1956

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Corporate governance

OncoZenge AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.